

Stuart A Rushworth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4172852/publications.pdf>

Version: 2024-02-01

96
papers

3,492
citations

168829

31
h-index

162838

57
g-index

98
all docs

98
docs citations

98
times ranked

5606
citing authors

#	ARTICLE	IF	CITATIONS
1	LC3-associated phagocytosis in bone marrow macrophages suppresses acute myeloid leukemia progression through STING activation. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	26
2	Metabolic Regulation of Macrophages by SIRT1 Determines Activation During Cholestatic Liver Disease in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1019-1039.	2.3	14
3	PGC-1 α induced mitochondrial biogenesis in stromal cells underpins mitochondrial transfer to melanoma. <i>British Journal of Cancer</i> , 2022, 127, 69-78.	2.9	11
4	Modelling Metabolic Shifts during Cardiomyocyte Differentiation, Iron Deficiency and Transferrin Rescue Using Human Pluripotent Stem Cells. <i>Metabolites</i> , 2022, 12, 9.	1.3	7
5	Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells. <i>Haematologica</i> , 2021, 106, 589-592.	1.7	21
6	Mitochondrial oxidative phosphorylation in cutaneous melanoma. <i>British Journal of Cancer</i> , 2021, 124, 115-123.	2.9	39
7	Synthesis of Carboxamide-Containing Tranylcyproline Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia. <i>ChemMedChem</i> , 2021, 16, 1316-1324.	1.6	5
8	Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3813-3826.	2.9	5
9	Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia. <i>Biomarker Research</i> , 2021, 9, 35.	2.8	3
10	Mitochondria and the Tumour Microenvironment in Blood Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1329, 181-203.	0.8	1
11	BCL-XL Driven Accumulation of Dysfunctional Mitochondria in Aged Stromal Cells Impairs the Haematopoietic Stem Cell Response to Stress. <i>Blood</i> , 2021, 138, 1097-1097.	0.6	0
12	Multiple Myeloma Derived Mitochondrial Damps Induce Inflammation in the Bone Marrow Adipose Tissue Which Promotes Tumour Development. <i>Blood</i> , 2021, 138, 2654-2654.	0.6	0
13	LC3-Associated Phagocytosis in Bone Marrow Macrophages Suppresses AML Progression through Mitochondrial DAMP Induced Sting Activation. <i>Blood</i> , 2021, 138, 3441-3441.	0.6	0
14	Free fatty-acid transport via CD36 drives β -oxidation-mediated hematopoietic stem cell response to infection. <i>Nature Communications</i> , 2021, 12, 7130.	5.8	46
15	3098 " SINGLE-CELL ANALYSIS OF ALTERNATIVE SPLICING IN HEMATOPOIETIC STEM AND PROGENITOR CELLS. <i>Experimental Hematology</i> , 2021, 100, S89.	0.2	0
16	Trypanosoma brucei: Inhibition of cathepsin L is sufficient to kill bloodstream forms. <i>Molecular and Biochemical Parasitology</i> , 2020, 235, 111246.	0.5	7
17	Bone Marrow Senescence and the Microenvironment of Hematological Malignancies. <i>Frontiers in Oncology</i> , 2020, 10, 230.	1.3	23
18	ARQ531: the therapy that targets multiple pathways in acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 2350-2352.	1.7	0

#	ARTICLE	IF	CITATIONS
19	Autophagy Driven Extracellular Vesicles in the Leukaemic Microenvironment. <i>Current Cancer Drug Targets</i> , 2020, 20, 501-512.	0.8	3
20	Enhanced Free Fatty Acid Uptake Via CD36 Promotes a Metabolic Switch to B-Oxidation within Hematopoietic Stem Cells in Response to Acute Infection. <i>Blood</i> , 2020, 136, 39-40.	0.6	1
21	Mitochondrial Function Is Impaired in a Subset of Aged Haematopoietic Stem Cells in Response to Infection. <i>Blood</i> , 2020, 136, 27-28.	0.6	0
22	Investigating the Dual Targeting of BCL-2 and CD38 in Models of Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 10-10.	0.6	0
23	Myeloma Derived Mitochondrial Damage Associated Molecular Patterns Promote Pro-Tumoral Expansion By Inducing a Pro-Inflammatory Signature in the Bone Marrow Microenvironment. <i>Blood</i> , 2020, 136, 1-1.	0.6	0
24	Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction. <i>Thrombosis Research</i> , 2019, 179, 64-68.	0.8	6
25	ROS-mediated PI3K activation drives mitochondrial transfer from stromal cells to hematopoietic stem cells in response to infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 24610-24619.	3.3	82
26	Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment. <i>Blood</i> , 2019, 133, 446-456.	0.6	67
27	CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma. <i>Cancer Research</i> , 2019, 79, 2285-2297.	0.4	156
28	Daratumumab Inhibits AML Metabolic Capacity and Tumor Growth through Inhibition of CD38 Mediated Mitochondrial Transfer from Bone Marrow Stromal Cells to Blasts in the Leukemic Microenvironment. <i>Blood</i> , 2019, 134, 1385-1385.	0.6	9
29	Acute Myeloid Leukemia Export Mitochondria in Extracellular Vesicles Which Induces Pro-Tumoral Changes in Bone Marrow Macrophages. <i>Blood</i> , 2019, 134, 1427-1427.	0.6	1
30	Myeloma Derived Extracellular Vesicles Containing Endoplasmic Reticulum Remodel the Bone Marrow Microenvironment Towards a Pro-Tumoral Senescent Phenotype. <i>Blood</i> , 2019, 134, 689-689.	0.6	0
31	Diffuse Large B Cell Lymphoma (DLBCL)-Released NM23-H1 Promotes Monocyte Survival and Inflammatory Cytokine Release: A Mechanistic Link between the Dual Impacts of NM23-H1 Expression and Reduced Lymphocyte:Monocyte Ratio in DLBCL Prognosis. <i>Blood</i> , 2019, 134, 2803-2803.	0.6	0
32	Free Fatty Acid Uptake By Hematopoietic Stem and Progenitor Cells Drives Immune Cell Expansion in Response to Salmonella Typhimurium infection. <i>Blood</i> , 2019, 134, 1197-1197.	0.6	1
33	Superoxide Drives PI3 Kinase Mediated Mitochondria Transfer from the Bone Marrow Microenvironment to Hematopoietic Stem Cells in Response to Salmonella Typhimurium. <i>Blood</i> , 2019, 134, 2490-2490.	0.6	0
34	HIF1 α drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia. <i>Oncogene</i> , 2018, 37, 2676-2686.	2.6	25
35	High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma. <i>Cancer Letters</i> , 2018, 412, 37-45.	3.2	32
36	Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYC. <i>Journal of Hematology and Oncology</i> , 2018, 11, 66.	6.9	19

#	ARTICLE	IF	CITATIONS
37	PGC-1 β driven mitochondrial biogenesis in stromal cells underpins mitochondrial trafficking to leukemic blasts. <i>Leukemia</i> , 2018, 32, 2073-2077.	3.3	17
38	All-Trans Retinoic Acid (ATRA) up-Regulates Cell Surface CD38 Expression Which Promotes Pro-Tumoral Mitochondrial Trafficking from Stromal Cells to Multiple Myeloma. <i>Blood</i> , 2018, 132, 3153-3153.	0.6	0
39	Stressed Hematopoiesis Induces Mitochondrial Trafficking to Hematopoietic Stem Cells. <i>Blood</i> , 2018, 132, 3849-3849.	0.6	0
40	NOX2 Derived Superoxide Induces Pro-Tumoral p16INK4a Driven Senescence in the AML Bone Marrow Microenvironment. <i>Blood</i> , 2018, 132, 2770-2770.	0.6	0
41	Inflammatory Differences in Plaque Erosion and Rupture in Patients With ST \ast Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	36
42	Front-line glioblastoma chemotherapeutic temozolomide is toxic to <i>Trypanosoma brucei</i> and potently enhances melarsoprol and eflornithine. <i>Experimental Parasitology</i> , 2017, 178, 45-50.	0.5	6
43	The bone marrow microenvironment â€œ Home of the leukemic blasts. <i>Blood Reviews</i> , 2017, 31, 277-286.	2.8	119
44	Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment. <i>Blood</i> , 2017, 129, 1320-1332.	0.6	226
45	NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts. <i>Blood</i> , 2017, 130, 1649-1660.	0.6	242
46	MIF-Induced Stromal PKC β /IL8 Is Essential in Human Acute Myeloid Leukemia. <i>Cancer Research</i> , 2017, 77, 303-311.	0.4	66
47	The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma. <i>Cancers</i> , 2017, 9, 29.	1.7	31
48	Pulling the plug â€œ halting cancer's theft of mitochondria. <i>Oncoscience</i> , 2017, 4, 173-174.	0.9	2
49	Targeting PI3K β and PI3K γ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. <i>Oncotarget</i> , 2016, 7, 39784-39795.	0.8	24
50	Trypanocidal and cysteine protease inhibitory activity of isopentyl caffeate is not linked in <i>Trypanosoma brucei</i> . <i>Parasitology Research</i> , 2016, 115, 4397-4403.	0.6	12
51	Dual Activation of NRF2 in Multiple Myeloma and Bone Marrow Mesenchymal Stromal Cells Regulates Chemotherapy Resistance. <i>Blood</i> , 2016, 128, 3287-3287.	0.6	4
52	Bone Marrow Mesenchymal Stromal Cells Transfer Their Mitochondria to Acute Myeloid Leukaemia Blasts to Support Their Proliferation and Survival. <i>Blood</i> , 2016, 128, 772-772.	0.6	2
53	Hypoxia Drives AML Proliferation in the Bone Marrow Microenvironment Via Macrophage Inhibitory Factor. <i>Blood</i> , 2016, 128, 1721-1721.	0.6	1
54	Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia. <i>Scientific Reports</i> , 2015, 5, 12949.	1.6	32

#	ARTICLE	IF	CITATIONS
55	Oxidative Stress Responses and NRF2 in Human Leukaemia. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-7.	1.9	48
56	Ibrutinib inhibits BTK-driven NF- κ B p65 activity to overcome bortezomib-resistance in multiple myeloma. <i>Cell Cycle</i> , 2015, 14, 2367-2375.	1.3	47
57	Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells. <i>Lancet Haematology</i> , 2015, 2, e204-e211.	2.2	22
58	Targeting KEAP1/NRF2 pathway to manipulate the expression of oncogenic and oncosuppressive miRNAs in human leukemia. <i>Molecular and Cellular Oncology</i> , 2015, 5, 0-0.	0.3	2
59	Macrophage Migration Inhibitory Factor Drives Multiple Myeloma IL-6/8 Pro-Survival Signals in the Tumor Microenvironment. <i>Blood</i> , 2015, 126, 2988-2988.	0.6	1
60	FABP4 Regulates Fatty Acid Transfer from Bone Marrow Adipocytes to Acute Myeloid Leukemia Blasts. <i>Blood</i> , 2015, 126, 3065-3065.	0.6	0
61	Protein Kinase C- α Dependent IL-8 Release Promotes Acute Myeloid Leukemia Blast Cell Survival in Co-Cultures with Bone Marrow Stromal Cells. <i>Blood</i> , 2015, 126, 3064-3064.	0.6	0
62	A Novel Feed-Forward Loop Involving the High Mobility Group A1 (HMGA1) Chromatin Remodeling Protein and cMYC in Acute Myeloid Leukemia Is Targeted By JQ1. <i>Blood</i> , 2015, 126, 2466-2466.	0.6	8
63	Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. <i>Oncotarget</i> , 2014, 5, 9930-9938.	0.8	63
64	Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. <i>Blood</i> , 2014, 123, 1229-1238.	0.6	101
65	Understanding life and death decisions in human leukaemias. <i>Biochemical Society Transactions</i> , 2014, 42, 747-751.	1.6	0
66	The BTK Inhibitor Ibrutinib Blocks SDF1/CXCR4 Mediated Migration of Acute Myeloid Leukemia Cells. <i>Blood</i> , 2014, 124, 915-915.	0.6	0
67	High Mobility Group A1 (HMGA1) Chromatin Remodeling Protein Mediates Crosstalk Between Acute Myeloid Leukemia Blasts & the Tumor Microenvironment. <i>Blood</i> , 2014, 124, 3564-3564.	0.6	1
68	BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF- κ B. <i>Cellular Signalling</i> , 2013, 25, 106-112.	1.7	99
69	Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. <i>Cell Cycle</i> , 2013, 12, 2144-2153.	1.3	64
70	Understanding the role of NRF2-regulated miRNAs in human malignancies. <i>Oncotarget</i> , 2013, 4, 1130-1142.	0.8	57
71	NRF2 Signaling Promotes Survival and Drug Resistance Of Acute Myeloid Leukaemia Through Induction Of Mir-125b-1. <i>Blood</i> , 2013, 122, 3741-3741.	0.6	1
72	Bortezomib induces heme oxygenase-1 expression in multiple myeloma. <i>Cell Cycle</i> , 2012, 11, 2248-2252.	1.3	41

#	ARTICLE	IF	CITATIONS
73	The high Nrf2 expression in human acute myeloid leukemia is driven by NF- κ B and underlies its chemo-resistance. <i>Blood</i> , 2012, 120, 5188-5198.	0.6	225
74	Micro RNAs as a new therapeutic target towards leukaemia signalling. <i>Cellular Signalling</i> , 2012, 24, 363-368.	1.7	16
75	Understanding the role of miRNA in regulating NF- κ B in blood cancer. <i>American Journal of Cancer Research</i> , 2012, 2, 65-74.	1.4	13
76	Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. <i>Oncotarget</i> , 2011, 2, 658-668.	0.8	67
77	Targeting the oncogenic role of miRNA in human cancer using naturally occurring compounds. <i>British Journal of Pharmacology</i> , 2011, 162, 346-348.	2.7	11
78	TNF Mediates the Sustained Activation of Nrf2 in Human Monocytes. <i>Journal of Immunology</i> , 2011, 187, 702-707.	0.4	63
79	Silencing FLIPL modifies TNF-induced apoptotic protein expression. <i>Cell Cycle</i> , 2011, 10, 1067-1072.	1.3	6
80	High Basal Nuclear Levels of Nrf2 in Acute Myeloid Leukemia Reduces Sensitivity to Proteasome Inhibitors. <i>Cancer Research</i> , 2011, 71, 1999-2009.	0.4	81
81	The Role of Nrf2 and Cytoprotection in Regulating Chemotherapy Resistance of Human Leukemia Cells. <i>Cancers</i> , 2011, 3, 1605-1621.	1.7	45
82	NF- κ B Inhibited Acute Myeloid Leukemia Cells Are Rescued from Apoptosis by Heme Oxygenase-1 Induction. <i>Cancer Research</i> , 2010, 70, 2973-2983.	0.4	64
83	FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. <i>Oncotarget</i> , 2010, 1, 359-366.	0.8	31
84	FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. <i>Oncotarget</i> , 2010, 1, 359-66.	0.8	16
85	Molecular crosstalk between TRAIL and natural antioxidants in the treatment of cancer. <i>British Journal of Pharmacology</i> , 2009, 157, 1186-1188.	2.7	23
86	Epigallocatechin activates haem oxygenase-1 expression via protein kinase C γ and Nrf2. <i>Biochemical and Biophysical Research Communications</i> , 2008, 373, 584-588.	1.0	46
87	TNF signaling gets FLIPped off: TNF-induced regulation of FLIP. <i>Cell Cycle</i> , 2008, 7, 194-199.	1.3	12
88	Lipopolysaccharide-Induced Expression of NAD(P)H:Quinone Oxidoreductase 1 and Heme Oxygenase-1 Protects against Excessive Inflammatory Responses in Human Monocytes. <i>Journal of Immunology</i> , 2008, 181, 6730-6737.	0.4	177
89	HO-1 underlies resistance of AML cells to TNF-induced apoptosis. <i>Blood</i> , 2008, 111, 3793-3801.	0.6	127
90	Role of protein kinase C γ in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. <i>Biochemical and Biophysical Research Communications</i> , 2006, 341, 1007-1016.	1.0	160

#	ARTICLE	IF	CITATIONS
91	Lipopolysaccharide-Induced Heme Oxygenase-1 Expression in Human Monocytic Cells Is Mediated via Nrf2 and Protein Kinase C. <i>Journal of Immunology</i> , 2005, 175, 4408-4415.	0.4	171
92	±-Lipoic Acidâ€“Induced Heme Oxygenase-1 Expression Is Mediated by Nuclear Factor Erythroid 2-Related Factor 2 and p38 Mitogen-Activated Protein Kinase in Human Monocytic Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2100-2105.	1.1	113
93	HUMAN CD154 INDUCES ACTIVATION OF PORCINE ENDOTHELIAL CELLS AND UP-REGULATION OF MHC CLASS II EXPRESSION. <i>Transplantation</i> , 2001, 72, 127-132.	0.5	16
94	HIGH SEQUENCE HOMOLOGY BETWEEN HUMAN AND PIG CD40 WITH CONSERVED BINDING TO HUMAN CD154. <i>Transplantation</i> , 2000, 69, 936-940.	0.5	10
95	p16INK4A dependent senescence in the bone marrow niche drives age-related metabolic changes of hematopoietic progenitors. <i>Blood Advances</i> , 0, , .	2.5	4
96	Acute Myeloid Leukaemia Drives Metabolic Changes in the Bone Marrow Niche. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9